Clinical-stage biotech firm Seaport Therapeutics has raised approximately $255 million in its initial public offering. The offering was upsized and priced at the top of its expected range.
- Raised nearly $255 million in US IPO
- Shares priced at $18, the top of the $16-$18 range
- Offering upsized to 14.6 million shares from 11.8 million
- Funds to support neuro-psychiatry drug development
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.